Abstract: Isolated DNA of the Wtk1 gene or a functional equivalent capable of conferring resistance to stripe rust, is provided, as well as artificial vectors comprising same, proteins encoded by same and nucleic acid molecules for detecting same. Transgenic plants, as well as cells, seeds, and tissue therefrom which express the Wtk1 gene or a functional equivalent thereof are also provided.

Abstract: The present invention provides compounds useful as inhibitors of Ca2+/calmodulin-dependent protein kinase (CaMKII), compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds useful as inhibitors of Ca2+/calmodulin-dependent protein kinase (CaMKII), compositions thereof, and methods of using the same.

Abstract: Isolated DNA of the Wtk1 gene or a functional equivalent capable of conferring resistance to stripe rust, is provided, as well as artificial vectors comprising same, proteins encoded by same and nucleic acid molecules for detecting same. Transgenic plants, as well as cells, seeds, and tissue therefrom which express the Wtk1 gene or a functional equivalent thereof are also provided.

Abstract: The present invention provides compounds useful as inhibitors of Ca2+/calmodulin-dependent protein kinase (CaMKII), compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds useful as inhibitors of Ca2+/calmodulin-dependent protein kinase (CaMKII), compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds useful as inhibitors of Ca2+/calmodulin-dependent protein kinase (CaMKII), compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds useful as inhibitors of Ca2+/calmodulin-dependent protein kinase (CaMKII), compositions thereof, and methods of using the same.

Abstract: Compositions, methods and kits useful for the diagnosis, prognosis, and treatment of CNS lymphoma.

Abstract: This invention provides a method for treating or preventing arrhythmias in a human subject comprising the administration of an effective amount of a calcium/calmodulin-dependent protein kinase inhibitor. Also provided are pharmaceutical compositions comprising a calcium/calmodulin-dependent protein kinase inhibitor and a pharmaceutically acceptable carrier and methods for identifying agents useful for the treatment of arrhythmias.

Abstract: This invention provides a method for determining whether an agent inhibits binding between CaMKII and a Ca+2 channel. Furthermore, this invention provides a method for inhibiting binding between CaMKII and a Ca+2 channel in a cell. Finally, this invention provides methods of treating cardiac arrhythmia and neurological disorders.

Abstract: This invention provides a method for determining whether an agent inhibits phosphorylation of a calcium channel by CaMKII. Furthermore, this invention provides a method of inhibiting phosphorylation of a calcium channel by CaMKII in a cell. Finally, this invention provides methods for treating cardiac arrhythmia and neurological disorders.

Abstract: Biological markers for rheumatoid arthritis (RA) are disclosed. Also disclosed are the uses of such markers to diagnose and treat RA, monitor progression of the disease, evaluate therapeutic interventions, and screen candidate drugs in a clinical or preclinical trial.

Abstract: The present invention is related to a method and a test kit for demonstrating genetic identity, genetic diversity, genomic variations or polymorphisms, especially allelic variations, and also biodiversity within a defined population pool, with co-dominant scoring. The method and the test kit apply mobile elements (MEs) and are based on the use of one or more sets of optionally paired or parallel oligonucleotides, which are attached to a solid support. Each oligonucleotide sequence represents an insertion site junction of a mobile element (ME). The invention is also related to the use of the method and the test kit for phylogenetic studies, parenthood determinations, genotyping, haplotyping, pedigree analysis, forensic science, human medical diagnostics and in plant and animal breeding by demonstrating genetic identity, genetic diversity, genomic variation or polymorphism and particularly co-dominant scoring.

Abstract: This invention provides a method for treating or preventing arrhythmias in a human subject comprising the administration of an effective amount of a calcium/calmodulin-dependent protein kinase inhibitor. Also provided are pharmaceutical compositions comprising a calcium/calmodulin-dependent protein kinase inhibitor and a pharmaceutically acceptable carrier and methods for identifying agents useful for the treatment of arrhythmias.

Abstract: This invention provides a method for treating or preventing arrhythmias in a human subject comprising the administration of an effective amount of a calcium/calmodulin-dependent protein kinase inhibitor. Also provided are pharmaceutical compositions comprising a calcium/calmodulin-dependent protein kinase inhibitor and a pharmaceutically acceptable carrier and methods for identifying agents useful for the treatment of arrhythmias.

Abstract: Proteins are selectively extracted from complex biological mixtures for subsequent analysis by methods such as mass spectrometry. Protein-binding (e.g., PDZ or SH2) or cellular compartmentalizing (e.g., membrane-targeting) domains are provided to target specific proteins, and targeted proteins are enzymatically modified by attachment of modification molecules. For example, targeted proteins can be biotinylated by the enzyme biotin protein ligase. The protein-targeting domain and protein-modifying enzyme can be immobilized on a solid surface (macroscopic planar surface or particle surface), provided as a fusion protein, or chemically coupled. The modified proteins are then exposed to complementary molecules (e.g., avidin or streptavidin) that bind strongly to the modification molecule, resulting in affinity capture of the selected proteins.

Abstract: Bifunctional capture probes used for multiplexed assays consist of particles bearing analyte-binding moieties and pairing oligonucleotides, which hybridize to an array of surface-bound capture oligonucleotides. Capture probes are combined with a sample containing analytes of interest, extracted from the sample, and then exposed to the oligonucleotide array. Based on their pairing oligonucleotide sequences, the capture probes self-assemble at particular array locations. Bound analytes are then detected using a method, such as mass spectrometry, that can be directed toward particular array locations. Because any number and combination of capture probes can be employed, the method is flexible and able to detect analytes at very low concentrations. Additionally, the method provides the ease of detection associated with position-addressable arrays.